Agency has been calling for the vasculitis drug to be pulled from the market since January
— Agency has been calling for the vasculitis drug to be pulled from the market since January
by Ian Ingram, Managing Editor, MedPage Today
July 24, 2026
• 3 min read
Amgen has submitted a third-party review of avacopan's (Tavneos) pivotal trial data and other analyses to the FDA in a bid to keep the embattled drug for severe anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis on the market.
The FDA has proposed to withdraw its approval of avacopan for ANCA-associated vasculitis, alleging that employees of the original…
The New England Journal of Medicine has retracted its publication of the sole trial of avacopan used by the FDA to assess the…
Trial data 'can no longer be relied upon' to demonstrate drug's efficacy, EMA committee says
Move follows actions 'inconsistent with proper research conduct,' journal says
In this Healio video exclusive, Leonard H. Calabrese, DO, chief medical editor of Healio Rheumatology, highlights recent coverage…
Amgen has asked the FDA to review evidence that its drug Tavneos (avacopan), which treats a rare form of vasculitis, is worth…
